Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections
Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challengi...
Ausführliche Beschreibung
Autor*in: |
Giuseppe Pipitone [verfasserIn] Stefano Di Bella [verfasserIn] Alberto Enrico Maraolo [verfasserIn] Guido Granata [verfasserIn] Milo Gatti [verfasserIn] Luigi Principe [verfasserIn] Alessandro Russo [verfasserIn] Andrea Gizzi [verfasserIn] Rita Pallone [verfasserIn] Antonio Cascio [verfasserIn] Chiara Iaria [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Antibiotics - MDPI AG, 2013, 12(2023), 12, p 1653 |
---|---|
Übergeordnetes Werk: |
volume:12 ; year:2023 ; number:12, p 1653 |
Links: |
---|
DOI / URN: |
10.3390/antibiotics12121653 |
---|
Katalog-ID: |
DOAJ098922181 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ098922181 | ||
003 | DE-627 | ||
005 | 20240414004808.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240414s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/antibiotics12121653 |2 doi | |
035 | |a (DE-627)DOAJ098922181 | ||
035 | |a (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RM1-950 | |
100 | 0 | |a Giuseppe Pipitone |e verfasserin |4 aut | |
245 | 1 | 0 | |a Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. | ||
650 | 4 | |a fosfomycin | |
650 | 4 | |a <i<Pseudomonas aeruginosa</i< | |
650 | 4 | |a multidrug resistance | |
650 | 4 | |a difficult-to-treat <i<P. aeruginosa</i< | |
653 | 0 | |a Therapeutics. Pharmacology | |
700 | 0 | |a Stefano Di Bella |e verfasserin |4 aut | |
700 | 0 | |a Alberto Enrico Maraolo |e verfasserin |4 aut | |
700 | 0 | |a Guido Granata |e verfasserin |4 aut | |
700 | 0 | |a Milo Gatti |e verfasserin |4 aut | |
700 | 0 | |a Luigi Principe |e verfasserin |4 aut | |
700 | 0 | |a Alessandro Russo |e verfasserin |4 aut | |
700 | 0 | |a Andrea Gizzi |e verfasserin |4 aut | |
700 | 0 | |a Rita Pallone |e verfasserin |4 aut | |
700 | 0 | |a Antonio Cascio |e verfasserin |4 aut | |
700 | 0 | |a Chiara Iaria |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Antibiotics |d MDPI AG, 2013 |g 12(2023), 12, p 1653 |w (DE-627)726120596 |w (DE-600)2681345-2 |x 20796382 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2023 |g number:12, p 1653 |
856 | 4 | 0 | |u https://doi.org/10.3390/antibiotics12121653 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/2079-6382/12/12/1653 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2079-6382 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 12 |j 2023 |e 12, p 1653 |
author_variant |
g p gp s d b sdb a e m aem g g gg m g mg l p lp a r ar a g ag r p rp a c ac c i ci |
---|---|
matchkey_str |
article:20796382:2023----::nrvnufsoyifrytmcutdurssatpedmn |
hierarchy_sort_str |
2023 |
callnumber-subject-code |
RM |
publishDate |
2023 |
allfields |
10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653 |
spelling |
10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653 |
allfields_unstemmed |
10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653 |
allfieldsGer |
10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653 |
allfieldsSound |
10.3390/antibiotics12121653 doi (DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b DE-627 ger DE-627 rakwb eng RM1-950 Giuseppe Pipitone verfasserin aut Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology Stefano Di Bella verfasserin aut Alberto Enrico Maraolo verfasserin aut Guido Granata verfasserin aut Milo Gatti verfasserin aut Luigi Principe verfasserin aut Alessandro Russo verfasserin aut Andrea Gizzi verfasserin aut Rita Pallone verfasserin aut Antonio Cascio verfasserin aut Chiara Iaria verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 12, p 1653 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:12, p 1653 https://doi.org/10.3390/antibiotics12121653 kostenfrei https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b kostenfrei https://www.mdpi.com/2079-6382/12/12/1653 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 12, p 1653 |
language |
English |
source |
In Antibiotics 12(2023), 12, p 1653 volume:12 year:2023 number:12, p 1653 |
sourceStr |
In Antibiotics 12(2023), 12, p 1653 volume:12 year:2023 number:12, p 1653 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< Therapeutics. Pharmacology |
isfreeaccess_bool |
true |
container_title |
Antibiotics |
authorswithroles_txt_mv |
Giuseppe Pipitone @@aut@@ Stefano Di Bella @@aut@@ Alberto Enrico Maraolo @@aut@@ Guido Granata @@aut@@ Milo Gatti @@aut@@ Luigi Principe @@aut@@ Alessandro Russo @@aut@@ Andrea Gizzi @@aut@@ Rita Pallone @@aut@@ Antonio Cascio @@aut@@ Chiara Iaria @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
726120596 |
id |
DOAJ098922181 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098922181</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414004808.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics12121653</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098922181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giuseppe Pipitone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fosfomycin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multidrug resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">difficult-to-treat <i<P. aeruginosa</i<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Di Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Enrico Maraolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guido Granata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milo Gatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Principe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Gizzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rita Pallone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Cascio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Iaria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">12(2023), 12, p 1653</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:12, p 1653</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics12121653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/12/12/1653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">12, p 1653</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Giuseppe Pipitone |
spellingShingle |
Giuseppe Pipitone misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections |
authorStr |
Giuseppe Pipitone |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)726120596 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RM1-950 |
illustrated |
Not Illustrated |
issn |
20796382 |
topic_title |
RM1-950 Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections fosfomycin <i<Pseudomonas aeruginosa</i< multidrug resistance difficult-to-treat <i<P. aeruginosa</i< |
topic |
misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology |
topic_unstemmed |
misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology |
topic_browse |
misc RM1-950 misc fosfomycin misc <i<Pseudomonas aeruginosa</i< misc multidrug resistance misc difficult-to-treat <i<P. aeruginosa</i< misc Therapeutics. Pharmacology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Antibiotics |
hierarchy_parent_id |
726120596 |
hierarchy_top_title |
Antibiotics |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)726120596 (DE-600)2681345-2 |
title |
Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections |
ctrlnum |
(DE-627)DOAJ098922181 (DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b |
title_full |
Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections |
author_sort |
Giuseppe Pipitone |
journal |
Antibiotics |
journalStr |
Antibiotics |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
author_browse |
Giuseppe Pipitone Stefano Di Bella Alberto Enrico Maraolo Guido Granata Milo Gatti Luigi Principe Alessandro Russo Andrea Gizzi Rita Pallone Antonio Cascio Chiara Iaria |
container_volume |
12 |
class |
RM1-950 |
format_se |
Elektronische Aufsätze |
author-letter |
Giuseppe Pipitone |
doi_str_mv |
10.3390/antibiotics12121653 |
author2-role |
verfasserin |
title_sort |
intravenous fosfomycin for systemic multidrug-resistant <i<pseudomonas aeruginosa</i< infections |
callnumber |
RM1-950 |
title_auth |
Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections |
abstract |
Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. |
abstractGer |
Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. |
abstract_unstemmed |
Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
12, p 1653 |
title_short |
Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections |
url |
https://doi.org/10.3390/antibiotics12121653 https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b https://www.mdpi.com/2079-6382/12/12/1653 https://doaj.org/toc/2079-6382 |
remote_bool |
true |
author2 |
Stefano Di Bella Alberto Enrico Maraolo Guido Granata Milo Gatti Luigi Principe Alessandro Russo Andrea Gizzi Rita Pallone Antonio Cascio Chiara Iaria |
author2Str |
Stefano Di Bella Alberto Enrico Maraolo Guido Granata Milo Gatti Luigi Principe Alessandro Russo Andrea Gizzi Rita Pallone Antonio Cascio Chiara Iaria |
ppnlink |
726120596 |
callnumber-subject |
RM - Therapeutics and Pharmacology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/antibiotics12121653 |
callnumber-a |
RM1-950 |
up_date |
2024-07-03T20:00:31.217Z |
_version_ |
1803589340334391297 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098922181</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414004808.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics12121653</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098922181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5fab61fdcab54785a2464f804d11d18b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giuseppe Pipitone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravenous Fosfomycin for Systemic Multidrug-Resistant <i<Pseudomonas aeruginosa</i< Infections</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Human <i<Pseudomonas</i< infections have high morbidity and mortality rates. <i<Pseudomonas</i< bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against <i<Pseudomonas</i< is herein reviewed and discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fosfomycin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multidrug resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">difficult-to-treat <i<P. aeruginosa</i<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Di Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Enrico Maraolo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guido Granata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milo Gatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Principe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Gizzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rita Pallone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Cascio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Iaria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">12(2023), 12, p 1653</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:12, p 1653</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics12121653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5fab61fdcab54785a2464f804d11d18b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/12/12/1653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">12, p 1653</subfield></datafield></record></collection>
|
score |
7.4002275 |